Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients?
Aged
Aged, 80 and over
Antifibrinolytic Agents
/ therapeutic use
Arthroplasty, Replacement, Hip
Aspirin
/ therapeutic use
Blood Loss, Surgical
/ statistics & numerical data
Blood Transfusion
/ statistics & numerical data
Cardiovascular Diseases
/ epidemiology
Deprescriptions
Elective Surgical Procedures
Female
Humans
Male
Middle Aged
Mortality
Platelet Aggregation Inhibitors
/ therapeutic use
Postoperative Complications
/ epidemiology
Postoperative Hemorrhage
/ epidemiology
Retrospective Studies
Thromboembolism
/ epidemiology
Tranexamic Acid
/ therapeutic use
Aspirin
Perioperative complications
Postoperative period
Total hip arthroplasty
Journal
Archives of orthopaedic and trauma surgery
ISSN: 1434-3916
Titre abrégé: Arch Orthop Trauma Surg
Pays: Germany
ID NLM: 9011043
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
03
2020
accepted:
30
09
2020
pubmed:
12
10
2020
medline:
27
4
2021
entrez:
11
10
2020
Statut:
ppublish
Résumé
Acetylsalicylic acid (aspirin) is a commonly prescribed medication, especially in the age group of individuals who undergo elective total hip arthroplasty (THA). Preoperative discontinuation of aspirin is believed to reduce intraoperative bleeding and other complications, but it may increase the risk of perioperative cardiovascular events. In this study we have sought to evaluate the safety of continuous aspirin treatment in patients undergoing elective THA. This is a retrospective analysis of a consecutive cohort who underwent elective THA in a tertiary medical center between 2011 and 2018. The cohort was divided into two groups-one that received continuous preoperative aspirin treatment and one that did not. Blood loss, peri- and postoperative complications, readmissions, and short- and long-term mortality were compared between groups. Out of 757 consecutive patients (293 males, 464 females) who underwent elective primary THA, 552 were in the "non-aspirin" group and 205 were in the "aspirin" group and were not treated preoperative with other medication affecting hemostasis. Perioperative continuation of aspirin treatment did not significantly increase perioperative bleeding, as indicated by changes in hemoglobin levels (P = 0.72). There were no significant differences in short- and long-term mortality (P = 0.47 and P = 0.4, respectively) or other perioperative complications, such as readmission (P = 0.78), deep or superficial infection (P = 1 and P = 0.47, respectively), and cardiovascular events (none in both groups). Peri-operative continuation of aspirin treatment in patients undergoing elective primary THA did not increase perioperative complications or mortality compared to the non-aspirin-treated patients. The protective effects of aspirin from postoperative thrombotic and cardiovascular events are well documented. The current findings dispute the need to preoperatively withhold aspirin treatment in patients undergoing elective primary THA.
Identifiants
pubmed: 33040197
doi: 10.1007/s00402-020-03629-7
pii: 10.1007/s00402-020-03629-7
doi:
Substances chimiques
Antifibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Tranexamic Acid
6T84R30KC1
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM